Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China

• Published in: Vaccine Vol. 29; no. 22; pp. 3837 - 3841
• Main Authors: Sun, Caijun, Zhang, Yinfeng, Feng, Liqiang, Pan, Weiqi, Zhang, Maochao, Hong, Zheyu, Ma, Xin, Chen, Xiaoping, Chen, Ling
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 17.05.2011; Elsevier; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; Acquired Immunodeficiency Syndrome - complications; Adenoviridae infections; Adenoviridae Infections - epidemiology; Adenovirus; Adenoviruses; Adenoviruses, Human - immunology; Adolescent; Adult; Age; Aged; AIDS; Allergy and Immunology; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Antibody; Applied microbiology; Biological and medical sciences; blood; Child; China; Female; Fundamental and applied biological sciences. Psychology; Gene therapy; HIV; HIV infections; HIV,vaccine; Hospitals; Human immunodeficiency virus; Human viral diseases; Humans; immunity; Infections; Infectious diseases; Male; Medical sciences; Methods; Microbiology; Middle Aged; Miscellaneous; neutralization; neutralizing antibodies; patients; people; Population; Science; Seroepidemiologic Studies; seroprevalence; serotypes; Studies; surveys; vaccination; vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Virology; viruses; Young Adult; China; Asia; AIDS; Adenovirus; Antibody; HIV,vaccine; Human; Immunopathology; Adenoviridae; Retroviridae; Vaccine; Immune deficiency; Lentivirus; Epidemiology; Neutralizing antibody; Infection; Virus; Adenovirus 5; Human adenovirus; Viral disease; Mastadenovirus; Human immunodeficiency virus
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2011.03.042

Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.